Therapeutic Opportunities for Immunoreceptor-Engineered T Cell Therapy for Modulation of AlloimmunityKavitha Muralidharan(Parker Institute for Cancer Immunotherapy), Vijay Bhoj(Hospital of the University of Pennsylvania)The Journal of ImmunologyNovember 1, 202210.4049/jimmunol.2200542Cited by 3SaveCiteExport RISWatch citationsRelated PapersModulation of the gut microbiota engages antigen cross-presentation to enhance antitumor effects of CAR T cell immunotherapy|Molecular Therapy|2023|57